STUDY OBJECTIVE To assess effect of intravenous recombinant tissue type plasminogen activator on size of infarct, left ventricular function, and survival in acute myocardial infarction. DESIGN Double blind, randomised, placebo controlled prospective trial of patients with acute myocardial infarction within five hours after onset of symptoms. SETTING Twenty six referral centres participating...

Intracerebral hemorrhage (ICH) is the most serious complication of intravenous thrombolysis with recombinant tissue-type plasminogen activator (IV-r-tPA) in patients with ischemic stroke. The European Cooperative Acute Stroke Study (ECASS) defined remote parenchymal hemorrhages (rPH) as single or multiple hemorrhages that appear in brain regions without visible ischemic damage detected by crani...

reteplase is a segment of tissue plasminogen activator used for the removal of thrombi in blood vessels. in the present study the cloned reteplase gene was used for its expression in competent e. coli. the  recombinant plasmid, pet15b/reteplase (rpet-bl21), was transformed into competent e.coli strain bl21 (de3) cells. overnight culture of the transformed bacteria was induced by the addition of...

BACKGROUND Acute ischaemic stroke is common in older people. There is one licensed acute treatment, intravenous recombinant tissue plasminogen activator, but little information is available on its safety in over 80 year olds. DESIGN Review of prospectively collected data on 62 consecutive patients, aged 80 years and over, treated with recombinant tissue plasminogen activator in a tertiary cen...

BACKGROUND AND PURPOSE The benefits and safety of thrombolytic therapy was studied in patients with acute brain embolism. METHODS We intravenously administered recombinant tissue plasminogen activator (20-30 MU for 1 hour) to 10 patients with acute (less than 6 hours) brain embolism and examined the neurological outcomes in relation to the findings on computed tomography and angiography. RE...

The mechanism by which transitional tumor cells adhere to areas of urothelial injury and the means by which heparin prevents this phenom enon were studied. Scanning electron microscopy and a radiolabeled tumor cell adherence assay were used to assess the activity of heparin and a "nonglycosaminoglycan" thrombolytic agent, recombinant tissue plasminogen activator, in preventing tumor cell adhere...